glycine has been researched along with Familial Waldenstrom's Macroglobulinaemia in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 9.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 5.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Castillo, JJ | 1 |
| Meid, K | 1 |
| Flynn, CA | 1 |
| Chen, J | 1 |
| Demos, MG | 1 |
| Guerrera, ML | 1 |
| Kofides, A | 1 |
| Liu, X | 1 |
| Munshi, M | 1 |
| Tsakmaklis, N | 1 |
| Patterson, CJ | 1 |
| Yang, G | 1 |
| Hunter, Z | 1 |
| Treon, SP | 1 |
| Ma, W | 1 |
| Zhao, J | 1 |
| Zhang, L | 1 |
| Smolewski, P | 1 |
| Rydygier, D | 1 |
| BERLIN, NI | 1 |
| Virella, G | 1 |
| Lopes-Virella, MF | 1 |
| Andersen, BR | 1 |
| Tesar, JT | 1 |
| Schmid, FR | 1 |
| Haisty, WK | 1 |
| Hartz, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia[NCT02400437] | Phase 2 | 26 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The duration of response is measured from the time a participant achieved a response until the date of progression. (NCT02400437)
Timeframe: From the time each participant achieved a response to time of disease progression, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 33 |
Overall response includes the rate of complete response (CR), partial response (PR), minimal response (MR), stabl disease (SD) and progressive disease (PD). Minor response is >25%-50% reduction in serum IgM from baseline. Partial Response is (>50-90% reduction in serum IgM from baseline. Very Good Partial Response is >90% reduction in serum IgM from baseline. Complete Response is resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly. (NCT02400437)
Timeframe: 2 Years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 25 |
To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or >25% reduction in serum IgM from baseline. (NCT02400437)
Timeframe: 2 Years
| Intervention | Participants (Count of Participants) |
|---|---|
| MYD88 Mutated, CXCR4 Wild-type | 11 |
| MYD88 Mutated, CXCR4 Mutated | 14 |
Duration of time from start of treatment to disease progression. Progressive disease is defined as occurring when a >25% increase in serum IgM and an absolute 500mg/dL increase in IgM level occurs from the lowest attained response value, or progression of clinically significant disease related symptoms. (NCT02400437)
Timeframe: From start of treatment to time of disease progression, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 33 |
Duration from start of protocol treatment to time of initiation of new therapy. (NCT02400437)
Timeframe: From start of treatment until the participant begins a new therapy, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 39 |
Duration of time from start of treatment to time of disease progression. (NCT02400437)
Timeframe: From start of treatment to time of disease progression, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 33 |
Rate of very good partial response or better in patients treated with IDR. VGPR is defined as a >90% reduction in serum IgM levels from baseline. (NCT02400437)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 5 |
2 reviews available for glycine and Familial Waldenstrom's Macroglobulinaemia
| Article | Year |
|---|---|
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Boron Compounds; Dexamethasone; Drugs, Investi | 2019 |
DETERMINATION OF RED BLOOD CELL LIFE SPAN.
Topics: Anemia; Carbon Isotopes; Chromium Isotopes; Erythrocytes; Glycine; Hemoglobins; Hemoglobins, Abnorma | 1964 |
1 trial available for glycine and Familial Waldenstrom's Macroglobulinaemia
| Article | Year |
|---|---|
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Topics: Boron Compounds; Dexamethasone; Follow-Up Studies; Glycine; Humans; Myeloid Differentiation Factor 8 | 2020 |
3 other studies available for glycine and Familial Waldenstrom's Macroglobulinaemia
| Article | Year |
|---|---|
A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boron Compo | 2021 |
Effects of therapeutically useful thiols (DL-penicillamine and alpha-mercaptopropionylglycine) on immunoglobulins.
Topics: Agammaglobulinemia; Blood Viscosity; Chromatography, Gel; Cryoglobulins; Electrophoresis; gamma-Glob | 1970 |
Biological and physical properties of a human m-cryoglobulin and its monomer subunit.
Topics: Alkylation; Binding Sites; Blood Proteins; Carbohydrates; Chemical Precipitation; Complement Fixatio | 1971 |